Physician profile
Jack Rubin
NPI 1700882479
$3,890.11
in general payments reported to CMS, 2019-2025
28 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $444 · 2021: $269 · 2022: $412 · 2023: $568 · 2024: $790 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $706.82 | 2020-2025 | Jynarque, Voyxact |
| Amgen INC. | $366.91 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $332.04 | 2021-2025 | |
| Akebia Therapeutics INC | $232.66 | 2019-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $227.72 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $219.23 | 2022-2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $192.47 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $191.56 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $164.09 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $163.17 | 2020-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $155.80 | 2021-2024 | Benlysta, Trelegy Ellipta |
| Boston Scientific Corporation | $155.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.45 | 2021-2025 | Jardiance |
| Vifor Pharma, INC. | $124.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $95.03 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $66.71 | 2025 | |
| Lilly USA, LLC | $54.96 | 2022-2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $50.70 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $42.27 | 2022-2023 | |
| Cmp Pharma, INC. | $37.50 | 2021 | |
| Travere Therapeutics, INC. | $30.96 | 2025 | |
| Lundbeck LLC | $30.30 | 2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $23.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.74 | 2019 | |
| Pfizer INC. | $19.23 | 2024 | |
| Mallinckrodt Hospital Products INC. | $18.55 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.61 | 2022 | |
| Siemens Medical Solutions USA, INC. | $14.47 | 2025 | Cios Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.